Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response

被引：0

作者：

Panaccione, Remo ^{[1
]}

Abreu, Maria T. ^{[2
]}

Lazariciu, Irina ^{[3
]}

Mundayat, Rajiv ^{[3
]}

Lawendy, Nervin ^{[4
]}

Salese, Leonardo ^{[4
]}

Woolcott, John C. ^{[4
]}

Sands, Bruce E. ^{[5
]}

Chaparro, Maria ^{[6
,7
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Inflammatory Bowel Dis Clin, Gastrointestinal Res, Calgary, AB, Canada

[2] Univ Miami, Miller Sch Med, Crohns & Colitis Ctr, Miami, FL 33136 USA

[3] Pfizer Inc, New York, NY USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA

[6] Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP, Madrid, Spain

[7] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S761

引用

页码：S351 / S352

页数：2

共 50 条

[21] EFFICACY OF TOFACITINIB DOSE ESCALATION TO 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS AFTER COMPLETING MAINTENANCE THERAPY IN REMISSION AND LOSING RESPONSE: DATA FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
Rubin, David T.
Dubinsky, Marla C.
Panes, Julian
Wu, Deng-Chyang
Lawendy, Nervin
Guo, Xiang
Lai, Chacun
Kwok, Kenneth
Su, Chinyu
Salese, Leonardo
GASTROENTEROLOGY, 2020, 158 (06) : S1195 - S1195
[22] CLINICAL OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB MONOTHERAPY IN THE OPEN-LABEL LONG-TERM EXTENSION
Fleischmann, R.
Wollenhaupt, J.
Wang, L.
Maniccia, A.
Kwok, K.
Takiya, L.
van Vollenhoven, R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 259 - 260
[23] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
Lichtenstein, Gary R.
Loftus, Edward V.
Wei, Shu Chen
Damiao, Aderson O.
Judd, Donna
Lawendy, Nervin
Chan, Gary
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Bloom, Stuart
GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
[24] Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study
Chiorean, Michael
Vermeire, Severine
Panes, Julian
Peyrin-Biroulet, Laurent
Zhang, Jinkun
Sands, Bruce E.
Lazin, Krisztina
Cabell, Chris H.
Naik, Snehal U.
Klassen, Preston
Sandborn, William J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S445 - S446
[25] Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
Vermeire, Severine
Chiorean, Michael
Panes, Julian
Peyrin-Biroulet, Laurent
Zhang, Jinkun
Sands, Bruce E.
Lazin, Krisztina
Klassen, Preston
Naik, Snehal U.
Cabell, Christopher H.
Sandborn, William J.
JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 950 - 959
[26] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
Lichtenstein, G. R.
Loftus, E. V., Jr.
Wei, S. C.
Damiao, A. O.
Judd, D.
Lawendy, N.
Chan, G.
Zhang, H.
Wang, W.
Thorpe, A. J.
Bloom, S.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
[27] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Brunner, Hermine I.
Akikusa, Jonathan D.
Al-Abadi, Eslam
Bohnsack, John F.
Boteanu, Alina Lucica
Chedeville, Gaelle
Cuttica, Ruben
De La Pena, Wendy
Jung, Lawrence
Kasapcopur, Ozgur
Kobusinska, Katarzyna
Schulert, Grant S.
Neiva, Claudia
Rivas-Chacon, Rafael
Rizo Rodriguez, Juan Cruz
Vazquez-Del Mercado, Monica
Wagner-Weiner, Linda
Weiss, Jennifer E.
Wouters, Carine
Posner, Holly
Wouters, Ann
Chang, Cheng
White, Claire
Kanik, Keith
Liu, Shixue
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
[28] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Brunner, Hermine I.
Akikusa, Jonathan D.
Al-Abadi, Eslam
Bohnsack, John F.
Boteanu, Alina Lucica
Chedeville, Gaelle
Cuttica, Ruben
De La Pena, Wendy
Jung, Lawrence
Kasapcopur, Ozgur
Kobusinska, Katarzyna
Schulert, Grant S.
Neiva, Claudia
Rivas-Chacon, Rafael
Rizo Rodriguez, Juan Cruz
Vazquez-Del Mercado, Monica
Wagner-Weiner, Linda
Weiss, Jennifer E.
Wouters, Carine
Posner, Holly
Wouters, Ann
Chang, Cheng
White, Claire
Kanik, Keith
Liu, Shixue
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
[29] Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Fleischmann, Roy
Yazici, Yusuf
Wollenhaupt, Juergen
Wang, Lisy
Maniccia, Anna
Kwok, Kenneth
Takiya, Liza
van Vollenhoven, Ronald
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[30] Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Devinsky, Orrin
Nabbout, Rima
Miller, Ian
Laux, Linda
Zolnowska, Marta
Wright, Stephen
Roberts, Claire
EPILEPSIA, 2019, 60 (02) : 294 - 302

← 1 2 3 4 5 →